Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure

Journal of Hepatology

Volumn 65, Issue 6, 2016, Pages 1217-1231

  van Mierlo, Kim M C ^a   Schaap, Frank G ^a   Dejong, Cornelis H C ^a,b   Olde Damink, Steven W M ^a,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatic cancer; Liver regeneration; Liver resection; Postresectional liver failure; Review

Indexed keywords

ANTINEOPLASTIC AGENT; BILE SALT;

CANCER CHEMOTHERAPY; CHEMOTHERAPY ASSOCIATED LIVER INJURY; CHOLESTASIS; ELECTIVE SURGERY; FATTY LIVER; HEMODYNAMICS; HUMAN; INNATE IMMUNITY; INTESTINE FLORA; LIVER CANCER; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION; LIVER HYPERPLASIA; LIVER METABOLISM; LIVER REGENERATION; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER VENOOCCLUSIVE DISEASE; LIVER WEIGHT; NODULAR REGENERATIVE HYPERPLASIA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS; LIVER FUNCTION TEST; LIVER TUMOR;

HEPATECTOMY; HUMANS; LIVER FAILURE; LIVER FUNCTION TESTS; LIVER NEOPLASMS;

EID: 84995451805     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.06.006     Document Type: Review

References (178)

1. [1] van den Broek, M.A., Olde Damink, S.W., Dejong, C.H., Lang, H., Malago, M., Jalan, R., et al. Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment. Liver Int 28 (2008), 767–780.
2. [2] Schindl, M.J., Redhead, D.N., Fearon, K.C., Garden, O.J., Wigmore, S.J., Edinburgh Liver, S., et al. The value of residual liver volume as a predictor of hepatic dysfunction and infection after major liver resection. Gut 54 (2005), 289–296.
3. [3] Balzan, S., Belghiti, J., Farges, O., Ogata, S., Sauvanet, A., Delefosse, D., et al. The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg 242 (2005), 824–828 [Discussion 828–829].
4. [4] Mullen, J.T., Ribero, D., Reddy, S.K., Donadon, M., Zorzi, D., Gautam, S., et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg 204 (2007), 854–862 [Discussion 862–854].
5. [5] Rahbari, N.N., Garden, O.J., Padbury, R., Brooke-Smith, M., Crawford, M., Adam, R., et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149 (2011), 713–724.
6. [6] Fausto, N., Campbell, J.S., Riehle, K.J., Liver regeneration. J Hepatol 57 (2012), 692–694.
7. [7] Michalopoulos, G.K., Principles of liver regeneration and growth homeostasis. Compr Physiol 3 (2013), 485–513.
8. [8] Vauthey, J.N., Abbott, D.E., Commentary on “Feasibility study of two-stage hepatectomy for bilobar liver metastases”. Am J Surg 203 (2012), 698–699.
9. [9] Eipel, C., Abshagen, K., Vollmar, B., Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol 16 (2010), 6046–6057.
10. [10] Allard, M.A., Adam, R., Bucur, P.O., Termos, S., Cunha, A.S., Bismuth, H., et al. Posthepatectomy portal vein pressure predicts liver failure and mortality after major liver resection on noncirrhotic liver. Ann Surg 258 (2013), 822–829 [Discussion 829–830].
11. [11] Golriz, M., Majlesara, A., El Sakka, S., Ashrafi, M., Arwin, J., Fard, N., et al. Small for Size and Flow (SFSF) syndrome: an alternative description for posthepatectomy liver failure. Clin Res Hepatol Gastroenterol 40 (2016), 267–275.
12. [12] Erlinger, S., Arias, I.M., Dhumeaux, D., Inherited disorders of bilirubin transport and conjugation: new insights into molecular mechanisms and consequences. Gastroenterology 146 (2014), 1625–1638.
13. [13] Doignon, I., Julien, B., Serriere-Lanneau, V., Garcin, I., Alonso, G., Nicou, A., et al. Immediate neuroendocrine signaling after partial hepatectomy through acute portal hyperpressure and cholestasis. J Hepatol 54 (2011), 481–488.
14. [14] Pean, N., Doignon, I., Garcin, I., Besnard, A., Julien, B., Liu, B., et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology 58 (2013), 1451–1460.
15. [15] Huang, W., Ma, K., Zhang, J., Qatanani, M., Cuvillier, J., Liu, J., et al. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 312 (2006), 233–236.
16. [16] Perez, M.J., Briz, O., Bile-acid-induced cell injury and protection. World J Gastroenterol 15 (2009), 1677–1689.
17. [17] Uriarte, I., Fernandez-Barrena, M.G., Monte, M.J., Latasa, M.U., Chang, H.C., Carotti, S., et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 62 (2013), 899–910.
18. [18] Fan, M., Wang, X., Xu, G., Yan, Q., Huang, W., Bile acid signaling and liver regeneration. Biochim Biophys Acta 1849 (2015), 196–200.
19. [19] Fausto, N., Campbell, J.S., Riehle, K.J., Liver regeneration. Hepatology 43 (2006), S45–S53.
20. [20] Chen, Y., Sun, R., Toll-like receptors in acute liver injury and regeneration. Int Immunopharmacol 11 (2011), 1433–1441.
21. [21] Takeishi, T., Hirano, K., Kobayashi, T., Hasegawa, G., Hatakeyama, K., Naito, M., The role of Kupffer cells in liver regeneration. Arch Histol Cytol 62 (1999), 413–422.
22. [22] Prins, H.A., Meijer, C., Boelens, P.G., Diks, J., Holtz, R., Masson, S., et al. Kupffer cell-depleted rats have a diminished acute-phase response following major liver resection. Shock 21 (2004), 561–565.
23. [23] Schindl, M.J., Millar, A.M., Redhead, D.N., Fearon, K.C., Ross, J.A., Dejong, C.H., et al. The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg 243 (2006), 507–514.
24. [24] Liu, H.X., Keane, R., Sheng, L., Wan, Y.J., Implications of microbiota and bile acid in liver injury and regeneration. J Hepatol 63 (2015), 1502–1510.
25. [25] Liu, H.X., Rocha, C.S., Dandekar, S., Yvonne Wan, Y.J., Functional analysis of the relationship between intestinal microbiota and the expression of hepatic genes and pathways during the course of liver regeneration. J Hepatol 64 (2016), 641–650.
26. [26] Joyce, S.A., MacSharry, J., Casey, P.G., Kinsella, M., Murphy, E.F., Shanahan, F., et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111 (2014), 7421–7426.
27. [27] Sayin, S.I., Wahlstrom, A., Felin, J., Jantti, S., Marschall, H.U., Bamberg, K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17 (2013), 225–235.
28. [28] Liu, H.X., Hu, Y., Wan, Y.Y., Microbiota and bile acid profiles in retinoic acid-primed mice that exhibit accelerated liver regeneration. Oncotarget 7 (2016), 1096–1106.
29. [29] Cornell, R.P., Gut-derived endotoxin elicits hepatotrophic factor secretion for liver regeneration. Am J Physiol 249 (1985), R551–R562.
30. [30] Cornell, R.P., Restriction of gut-derived endotoxin impairs DNA synthesis for liver regeneration. Am J Physiol 249 (1985), R563–R569.
31. [31] Rubbia-Brandt, L., Audard, V., Sartoretti, P., Roth, A.D., Brezault, C., Le Charpentier, M., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004), 460–466.
32. [32] Nakano, H., Oussoultzoglou, E., Rosso, E., Casnedi, S., Chenard-Neu, M.P., Dufour, P., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247 (2008), 118–124.
33. [33] Soubrane, O., Brouquet, A., Zalinski, S., Terris, B., Brezault, C., Mallet, V., et al. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg 251 (2010), 454–460.
34. [34] Vigano, L., Ravarino, N., Ferrero, A., Motta, M., Torchio, B., Capussotti, L., Prospective evaluation of accuracy of liver biopsy findings in the identification of chemotherapy-associated liver injuries. Arch Surg 147 (2012), 1085–1091.
35. [35] Schiffer, E., Frossard, J.L., Rubbia-Brandt, L., Mentha, G., Pastor, C.M., Hepatic regeneration is decreased in a rat model of sinusoidal obstruction syndrome. J Surg Oncol 99 (2009), 439–446.
36. [36] Hubert, C., Dahrenmoller, C., Marique, L., Jabbour, N., Gianello, P., Leclercq, I., Hepatic regeneration in a rat model is impaired by chemotherapy agents used in metastatic colorectal cancer. Eur J Surg Oncol 41 (2015), 1471–1478.
37. [37] Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M.B., Eng, C., et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110 (2007), 2761–2767.
38. [38] Rubbia-Brandt, L., Lauwers, G.Y., Wang, H., Majno, P.E., Tanabe, K., Zhu, A.X., et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56 (2010), 430–439.
39. [39] Imai, K., Emi, Y., Iyama, K.I., Beppu, T., Ogata, Y., Kakeji, Y., et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40 (2014), 559–566.
40. [40] Overman, M.J., Maru, D.M., Charnsangavej, C., Loyer, E.M., Wang, H., Pathak, P., et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28 (2010), 2549–2555.
41. [41] Ward, J., Guthrie, J.A., Sheridan, M.B., Boyes, S., Smith, J.T., Wilson, D., et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26 (2008), 4304–4310.
42. [42] Shin, N.Y., Kim, M.J., Lim, J.S., Park, M.S., Chung, Y.E., Choi, J.Y., et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 22 (2012), 864–871.
43. [43] Wanless, I.R., Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11 (1990), 787–797.
44. [44] Vigano, L., Rubbia-Brandt, L., De Rosa, G., Majno, P., Langella, S., Toso, C., et al. Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy: risk factors, preoperative assessment and clinical impact. Ann Surg Oncol 22 (2015), 4149–4157.
45. [45] van den Broek, M.A., Olde Damink, S.W., Driessen, A., Dejong, C.H., Bemelmans, M.H., Nodular regenerative hyperplasia secondary to neoadjuvant chemotherapy for colorectal liver metastases. Case Rep Med, 2009, 2009, 457975.
46. [46] Wicherts, D.A., de Haas, R.J., Sebagh, M., Ciacio, O., Levi, F., Paule, B., et al. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol 18 (2011), 659–669.
47. [47] Robinson, S.M., Wilson, C.H., Burt, A.D., Manas, D.M., White, S.A., Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol 19 (2012), 4287–4299.
48. [48] Vauthey, J.N., Pawlik, T.M., Ribero, D., Wu, T.T., Zorzi, D., Hoff, P.M., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006), 2065–2072.
49. [49] Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
50. [50] Little, S.A., Jarnagin, W.R., DeMatteo, R.P., Blumgart, L.H., Fong, Y., Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 6 (2002), 88–94.
51. [51] Newberry, E.P., Kennedy, S.M., Xie, Y., Luo, J., Stanley, S.E., Semenkovich, C.F., et al. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology 48 (2008), 1097–1105.
52. [52] de Meijer, V.E., Kalish, B.T., Puder, M., Ijzermans, J.N., Systematic review and meta-analysis of steatosis as a risk factor in major hepatic resection. Br J Surg 97 (2010), 1331–1339.
53. [53] Reddy, S.K., Marsh, J.W., Varley, P.R., Mock, B.K., Chopra, K.B., Geller, D.A., et al. Underlying steatohepatitis, but not simple hepatic steatosis, increases morbidity after liver resection: a case-control study. Hepatology 56 (2012), 2221–2230.
54. [54] Tashiro, H., Kuroda, S., Mikuriya, Y., Ohdan, H., Ischemia-reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery. Surg Today 44 (2014), 1611–1625.
55. [55] Vetelainen, R., van Vliet, A., Gouma, D.J., van Gulik, T.M., Steatosis as a risk factor in liver surgery. Ann Surg 245 (2007), 20–30.
56. [56] Selzner, M., Clavien, P.A., Failure of regeneration of the steatotic rat liver: disruption at two different levels in the regeneration pathway. Hepatology 31 (2000), 35–42.
57. [57] Yang, S.Q., Lin, H.Z., Mandal, A.K., Huang, J., Diehl, A.M., Disrupted signaling and inhibited regeneration in obese mice with fatty livers: implications for nonalcoholic fatty liver disease pathophysiology. Hepatology 34 (2001), 694–706.
58. [58] Myers, R.P., Fong, A., Shaheen, A.A., Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 28 (2008), 705–712.
59. [59] Regev, A., Berho, M., Jeffers, L.J., Milikowski, C., Molina, E.G., Pyrsopoulos, N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002), 2614–2618.
60. [60] de Moura, Almeida A., Cotrim, H.P., Barbosa, D.B., de Athayde, L.G., Santos, A.S., Bitencourt, A.G., et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol 14 (2008), 1415–1418.
61. [61] Lee, S.S., Park, S.H., Kim, H.J., Kim, S.Y., Kim, M.Y., Kim, D.Y., et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol 52 (2010), 579–585.
62. [62] Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., Cholongitas, E., Davidson, B.R., Burroughs, A.K., Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 54 (2011), 650–659.
63. [63] Loomba, R., Wolfson, T., Ang, B., Hooker, J., Behling, C., Peterson, M., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928.
64. [64] de Ledinghen, V., Vergniol, J., Foucher, J., El-Hajbi, F., Merrouche, W., Rigalleau, V., Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 30 (2010), 1043–1048.
65. [65] Shi, K.Q., Tang, J.Z., Zhu, X.L., Ying, L., Li, D.W., Gao, J., et al. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol 29 (2014), 1149–1158.
66. [66] Palmeri, M.L., Wang, M.H., Rouze, N.C., Abdelmalek, M.F., Guy, C.D., Moser, B., et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 55 (2011), 666–672.
67. [67] Shen, J., Chan, H.L., Wong, G.L., Choi, P.C., Chan, A.W., Chan, H.Y., et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 56 (2012), 1363–1370.
68. [68] Cusi, K., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60 (2014), 167–174.
69. [69] Sumida, Y., Yoneda, M., Hyogo, H., Itoh, Y., Ono, M., Fujii, H., et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol, 12, 2012, 2.
70. [70] Harrison, S.A., Oliver, D., Arnold, H.L., Gogia, S., Neuschwander-Tetri, B.A., Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 57 (2008), 1441–1447.
71. [71] Angulo, P., Hui, J.M., Marchesini, G., Bugianesi, E., George, J., Farrell, G.C., et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45 (2007), 846–854.
72. [72] Cales, P., Oberti, F., Michalak, S., Hubert-Fouchard, I., Rousselet, M.C., Konate, A., et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42 (2005), 1373–1381.
73. [73] Wai, C.T., Greenson, J.K., Fontana, R.J., Kalbfleisch, J.D., Marrero, J.A., Conjeevaram, H.S., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003), 518–526.
74. [74] de Lope, C.R., Tremosini, S., Forner, A., Reig, M., Bruix, J., Management of HCC. J Hepatol 56 (2012), S75–S87.
75. [75] Makuuchi, M., Sano, K., The surgical approach to HCC: our progress and results in Japan. Liver Transpl 10 (2004), S46–S52.
76. [76] Kuramitsu, K., Sverdlov, D.Y., Liu, S.B., Csizmadia, E., Burkly, L., Schuppan, D., et al. Failure of fibrotic liver regeneration in mice is linked to a severe fibrogenic response driven by hepatic progenitor cell activation. Am J Pathol 183 (2013), 182–194.
77. [77] Kato, A., Bamba, H., Shinohara, M., Yamauchi, A., Ota, S., Kawamoto, C., et al. Relationship between expression of cyclin D1 and impaired liver regeneration observed in fibrotic or cirrhotic rats. J Gastroenterol Hepatol 20 (2005), 1198–1205.
78. [78] Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol 60 (2014), 1310–1324.
79. [79] Vibhakorn, S., Cholongitas, E., Kalambokis, G., Manousou, P., Quaglia, A., Marelli, L., et al. A comparison of four- vs. three-pass transjugular biopsy using a 19-G Tru-Cut needle and a randomized study using a cassette to prevent biopsy fragmentation. Cardiovasc Intervent Radiol 32 (2009), 508–513.
80. [80] Wong, G.L., Espinosa, W.Z., Wong, V.W., Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Clin Mol Hepatol 21 (2015), 200–211.
81. [81] Bota, S., Herkner, H., Sporea, I., Salzl, P., Sirli, R., Neghina, A.M., et al. Meta-analysis: ARFI elastography vs. transient elastography for the evaluation of liver fibrosis. Liver Int 33 (2013), 1138–1147.
82. [82] Tsochatzis, E.A., Bosch, J., Burroughs, A.K., Liver cirrhosis. Lancet 383 (2014), 1749–1761.
83. [83] Verloh, N., Utpatel, K., Haimerl, M., Zeman, F., Fellner, C., Fichtner-Feigl, S., et al. Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: a histopathologic correlation. Sci Rep, 5, 2015, 15408.
84. [84] Lin, X.J., Yang, J., Chen, X.B., Zhang, M., Xu, M.Q., The critical value of remnant liver volume-to-body weight ratio to estimate posthepatectomy liver failure in cirrhotic patients. J Surg Res 188 (2014), 489–495.
85. [85] Chen, X., Zhai, J., Cai, X., Zhang, Y., Wei, L., Shi, L., et al. Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis. Br J Surg 99 (2012), 1701–1710.
86. [86] Cucchetti, A., Cescon, M., Golfieri, R., Piscaglia, F., Renzulli, M., Neri, F., et al. Hepatic venous pressure gradient in the preoperative assessment of patients with resectable hepatocellular carcinoma. J Hepatol 64 (2016), 79–86.
87. [87] Desmet, V.J., Histopathology of cholestasis. Verh Dtsch Ges Pathol 79 (1995), 233–240.
88. [88] Razumilava, N., Gores, G.J., Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 11 (2013), 13–21, e11 [Quiz e13–e14].
89. [89] Neuhaus, P., Thelen, A., Jonas, S., Puhl, G., Denecke, T., Veltzke-Schlieker, W., et al. Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 19 (2012), 1602–1608.
90. [90] Nuzzo, G., Giuliante, F., Ardito, F., Giovannini, I., Aldrighetti, L., Belli, G., et al. Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147 (2012), 26–34.
91. [91] Wiggers, J.K., Koerkamp, B.G., Cieslak, K.P., Doussot, A., van Klaveren, D., Allen, P.J., et al. Postoperative mortality after liver resection for perihilar cholangiocarcinoma: development of a risk score and importance of biliary drainage of the future liver remnant. J Am Coll Surg, 223, 2016 321–331.e1.
92. [92] Endo, I., Gonen, M., Yopp, A.C., Dalal, K.M., Zhou, Q., Klimstra, D., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 248 (2008), 84–96.
93. [93] Yokoyama, Y., Nagino, M., Nimura, Y., Mechanism of impaired hepatic regeneration in cholestatic liver. J Hepatobiliary Pancreat Surg 14 (2007), 159–166.
94. [94] Tracy, T.F. Jr., Bailey, P.V., Goerke, M.E., Sotelo-Avila, C., Weber, T.R., Cholestasis without cirrhosis alters regulatory liver gene expression and inhibits hepatic regeneration. Surgery 110 (1991), 176–182 [Discussion 182–173].
95. [95] Yoshidome, H., Miyazaki, M., Shimizu, H., Ito, H., Nakagawa, K., Ambiru, S., et al. Obstructive jaundice impairs hepatic sinusoidal endothelial cell function and renders liver susceptible to hepatic ischemia/reperfusion. J Hepatol 33 (2000), 59–67.
96. [96] Gehring, S., Dickson, E.M., San Martin, M.E., van Rooijen, N., Papa, E.F., Harty, M.W., et al. Kupffer cells abrogate cholestatic liver injury in mice. Gastroenterology 130 (2006), 810–822.
97. [97] Morita, Y., Yoshidome, H., Kimura, F., Shimizu, H., Ohtsuka, M., Takeuchi, D., et al. Excessive inflammation but decreased immunological response renders liver susceptible to infection in bile duct ligated mice. J Surg Res 146 (2008), 262–270.
98. [98] Kuzu, M.A., Kale, I.T., Col, C., Tekeli, A., Tanik, A., Koksoy, C., Obstructive jaundice promotes bacterial translocation in humans. Hepatogastroenterology 46 (1999), 2159–2164.
99. [99] Liver EAftSot. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009), 237–267.
100. [100] Mosler, P., Diagnosis and management of acute cholangitis. Curr Gastroenterol Rep 13 (2011), 166–172.
101. [101] van der Vorst, J.R., van Dam, R.M., van Stiphout, R.S., van den Broek, M.A., Hollander, I.H., Kessels, A.G., et al. Virtual liver resection and volumetric analysis of the future liver remnant using open source image processing software. World J Surg 34 (2010), 2426–2433.
102. [102] Dello, S.A., van Dam, R.M., Slangen, J.J., van de Poll, M.C., Bemelmans, M.H., Greve, J.W., et al. Liver volumetry plug and play: do it yourself with ImageJ. World J Surg 31 (2007), 2215–2221.
103. [103] Mao, Y., Du, S., Ba, J., Li, F., Yang, H., Lu, X., et al. Using Dynamic 99mT c-GSA SPECT/CT fusion images for hepatectomy planning and postoperative liver failure prediction. Ann Surg Oncol 22 (2015), 1301–1307.
104. [104] Verloh, N., Haimerl, M., Zeman, F., Schlabeck, M., Barreiros, A., Loss, M., et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol 24 (2014), 1013–1019.
105. [105] de Graaf, W., van Lienden, K.P., van Gulik, T.M., Bennink, R.J., (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J Nucl Med 51 (2010), 229–236.
106. [106] Robinson, S.M., Mann, J., Vasilaki, A., Mathers, J., Burt, A.D., Oakley, F., et al. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol 59 (2013), 318–326.
107. [107] Benimetskaya, L., Wu, S., Voskresenskiy, A.M., Echart, C., Zhou, J.F., Shin, J., et al. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Blood 112 (2008), 4343–4352.
108. [108] Brouquet, A., Benoist, S., Julie, C., Penna, C., Beauchet, A., Rougier, P., et al. Risk factors for chemotherapy-associated liver injuries: a multivariate analysis of a group of 146 patients with colorectal metastases. Surgery 145 (2009), 362–371.
109. [109] Ezzat, T., van den Broek, M.A., Davies, N., Dejong, C.H., Bast, A., Malago, M., et al. The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats. J Surg Oncol 106 (2012), 72–78.
110. [110] Schwarz, L., Faitot, F., Soubrane, O., Scatton, O., Splenic artery ligation for severe oxaliplatin induced portal hypertension: a way to improve postoperative course and allow adjuvant chemotherapy for colorectal liver metastases: Letter to editor: comment about “Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases”. Eur J Surg Oncol 40 (2014), 787–788.
111. [111] Doyle A, Dillon J, MacArthur M, Marquez M, Smith R, Grant D, et al. Treatment with optifast reduces hepatic steatosis and safely increases candidacy rates for live donor liver transplantation. The AASLD Liver Meeting, 2015.
112. [112] Reeves, J.G., Suriawinata, A.A., Ng, D.P., Holubar, S.D., Mills, J.B., Barth, R.J. Jr., Short-term preoperative diet modification reduces steatosis and blood loss in patients undergoing liver resection. Surgery 154 (2013), 1031–1037.
113. [113] Giannini, E., Borro, P., Botta, F., Fumagalli, A., Malfatti, F., Podesta, E., et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. J Hepatol 37 (2002), 572–577.
114. [114] Matsuo, R., Nakano, Y., Ohkohchi, N., Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. Ann Surg 253 (2011), 759–763.
115. [115] van der Gaag, N.A., Rauws, E.A., van Eijck, C.H., Bruno, M.J., van der Harst, E., Kubben, F.J., et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362 (2010), 129–137.
116. [116] Farges, O., Regimbeau, J.M., Fuks, D., Le Treut, Y.P., Cherqui, D., Bachellier, P., et al. Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 100 (2013), 274–283.
117. [117] Ferrero, A., Lo Tesoriere, R., Vigano, L., Caggiano, L., Sgotto, E., Capussotti, L., Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. World J Surg 33 (2009), 318–325.
118. [118] Hochwald, S.N., Burke, E.C., Jarnagin, W.R., Fong, Y., Blumgart, L.H., Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 134 (1999), 261–266.
119. [119] Kloek, J.J., van der Gaag, N.A., Aziz, Y., Rauws, E.A., van Delden, O.M., Lameris, J.S., et al. Endoscopic and percutaneous preoperative biliary drainage in patients with suspected hilar cholangiocarcinoma. J Gastrointest Surg 14 (2010), 119–125.
120. [120] Ishizawa, T., Hasegawa, K., Sano, K., Imamura, H., Kokudo, N., Makuuchi, M., Selective vs. total biliary drainage for obstructive jaundice caused by a hepatobiliary malignancy. Am J Surg 193 (2007), 149–154.
121. [121] van Lienden, K.P., van den Esschert, J.W., de Graaf, W., Bipat, S., Lameris, J.S., van Gulik, T.M., et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 36 (2013), 25–34.
122. [122] Pandanaboyana, S., Bell, R., Hidalgo, E., Toogood, G., Prasad, K.R., Bartlett, A., et al. A systematic review and meta-analysis of portal vein ligation vs. portal vein embolization for elective liver resection. Surgery 157 (2015), 690–698.
123. [123] Malinowski, M., Geisel, D., Stary, V., Denecke, T., Seehofer, D., Jara, M., et al. Portal vein embolization with plug/coils improves hepatectomy outcome. J Surg Res 194 (2015), 202–211.
124. [124] Hoekstra, L.T., van Lienden, K.P., Doets, A., Busch, O.R., Gouma, D.J., van Gulik, T.M., Tumor progression after preoperative portal vein embolization. Ann Surg 256 (2012), 812–817 [Discussion 817–818].
125. [125] Vetelainen, R., van Vliet, A.K., van Gulik, T.M., Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann Surg 245 (2007), 44–50.
126. [126] Narita, M., Oussoultzoglou, E., Chenard, M.P., Rosso, E., Casnedi, S., Pessaux, P., et al. Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. Surg Today 41 (2011), 7–17.
127. [127] de Baere, T., Teriitehau, C., Deschamps, F., Catherine, L., Rao, P., Hakime, A., et al. Predictive factors for hypertrophy of the future remnant liver after selective portal vein embolization. Ann Surg Oncol 17 (2010), 2081–2089.
128. [128] Farges, O., Belghiti, J., Kianmanesh, R., Regimbeau, J.M., Santoro, R., Vilgrain, V., et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237 (2003), 208–217.
129. [129] Schnitzbauer, A.A., Lang, S.A., Goessmann, H., Nadalin, S., Baumgart, J., Farkas, S.A., et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255 (2012), 405–414.
130. [130] Schadde, E., Ardiles, V., Robles-Campos, R., Malago, M., Machado, M., Hernandez-Alejandro, R., et al. Early survival and safety of ALPPS: first report of the International ALPPS Registry. Ann Surg 260 (2014), 829–836 [Discussion 836–828].
131. [131] Truant, S., Scatton, O., Dokmak, S., Regimbeau, J.M., Lucidi, V., Laurent, A., et al. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): impact of the inter-stages course on morbi-mortality and implications for management. Eur J Surg Oncol 41 (2015), 674–682.
132. [132] D'Haese, J.G., Neumann, J., Weniger, M., Pratschke, S., Bjornsson, B., Ardiles, V., et al. Should ALPPS be used for liver resection in intermediate-stage HCC?. Ann Surg Oncol 23 (2016), 1335–1343.
133. [133] Serenari, M., Zanello, M., Schadde, E., Toschi, E., Ratti, F., Gringeri, E., et al. Importance of primary indication and liver function between stages: results of a multicenter Italian audit of ALPPS 2012–2014. HPB 18 (2016), 419–427.
134. [134] Schadde, E., Malago, M., Hernandez-Alejandro, R., Li, J., Abdalla, E., Ardiles, V., et al. Monosegment ALPPS hepatectomy: extending resectability by rapid hypertrophy. Surgery 157 (2015), 676–689.
135. [135] Ren, Y.S., Qian, N.S., Tang, Y., Liao, Y.H., Liu, W.H., Raut, V., et al. Beneficial effects of splenectomy on liver regeneration in a rat model of massive hepatectomy. Hepatobiliary Pancreat Dis Int 11 (2012), 60–65.
136. [136] Ren, Z., Xu, Y., Zhu, S., The effect of terlipressin on hepatic hemodynamics in small-for-size livers. Hepatogastroenterology 59 (2012), 208–211.
137. [137] Fahrner, R., Patsenker, E., de Gottardi, A., Stickel, F., Montani, M., Stroka, D., et al. Elevated liver regeneration in response to pharmacological reduction of elevated portal venous pressure by terlipressin after partial hepatectomy. Transplantation 97 (2014), 892–900.
138. [138] Xu, X., Man, K., Zheng, S.S., Liang, T.B., Lee, T.K., Ng, K.T., et al. Attenuation of acute phase shear stress by somatostatin improves small-for-size liver graft survival. Liver Transpl 12 (2006), 621–627.
139. [139] Miki, C., Hiro, J., Ojima, E., Inoue, Y., Mohri, Y., Kusunoki, M., Perioperative allogeneic blood transfusion, the related cytokine response and long-term survival after potentially curative resection of colorectal cancer. Clin Oncol (R Coll Radiol) 18 (2006), 60–66.
140. [140] Simillis, C., Robertson, F.P., Afxentiou, T., Davidson, B.R., Gurusamy, K.S., A network metaanalysis comparing perioperative outcomes of interventions aiming to decrease ischemia reperfusion injury during elective liver resection. Surgery 159 (2016), 1157–1169.
141. [141] Datta, G., Fuller, B.J., Davidson, B.R., Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models. World J Gastroenterol 19 (2013), 1683–1698.
142. [142] van den Broek, M.A., Shiri-Sverdlov, R., Schreurs, J.J., Bloemen, J.G., Bieghs, V., Rensen, S.S., et al. Liver manipulation during liver surgery in humans is associated with hepatocellular damage and hepatic inflammation. Liver Int 33 (2013), 633–641.
143. [143] Belghiti, J., Guevara, O.A., Noun, R., Saldinger, P.F., Kianmanesh, R., Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 193 (2001), 109–111.
144. [144] Morise, Z., Ciria, R., Cherqui, D., Chen, K.H., Belli, G., Wakabayashi, G., Can we expand the indications for laparoscopic liver resection? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease. J Hepatobiliary Pancreat Sci 22 (2015), 342–352.
145. [145] Squires, M.H. 3rd, Lad, N.L., Fisher, S.B., Kooby, D.A., Weber, S.M., Brinkman, A., et al. Value of primary operative drain placement after major hepatectomy: a multi-institutional analysis of 1,041 patients. J Am Coll Surg 220 (2015), 396–402.
146. [146] Olthof, P.B., Coelen, R.J., Wiggers, J.K., Besselink, M.G., Busch, O.R., van Gulik, T.M., External biliary drainage following major liver resection for perihilar cholangiocarcinoma: impact on development of liver failure and biliary leakage. HPB 18 (2016), 348–353.
147. [147] Hirokawa, F., Hayashi, M., Miyamoto, Y., Asakuma, M., Shimizu, T., Komeda, K., et al. Evaluation of postoperative antibiotic prophylaxis after liver resection: a randomized controlled trial. Am J Surg 206 (2013), 8–15.
148. [148] Zhou, Y.M., Chen, Z.Y., Li, X.D., Xu, D.H., Su, X., Li, B., Preoperative antibiotic prophylaxis does not reduce the risk of postoperative infectious complications in patients undergoing elective hepatectomy. Dig Dis Sci 61 (2016), 1707–1713.
149. [149] Ren, W., Wang, X., Zhang, A., Li, C., Chen, G., Ge, X., et al. Selective bowel decontamination improves the survival of 90% hepatectomy in rats. J Surg Res 195 (2015), 454–464.
150. [150] Gurusamy, K.S., Nagendran, M., Davidson, B.R., Methods of preventing bacterial sepsis and wound complications after liver transplantation. Cochrane Database Syst Rev, 2014, CD006660.
151. [151] Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59 (2014), 2286–2298.
152. [152] Hollman, D.A., Milona, A., van Erpecum, K.J., van Mil, S.W., Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta 1821 (2012), 1443–1452.
153. [153] Schaap, F.G., Trauner, M., Jansen, P.L., Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol 11 (2014), 55–67.
154. [154] Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., Lavine, J.E., Van Natta, M.L., Abdelmalek, M.F., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
155. [155] Keitel, V., Donner, M., Winandy, S., Kubitz, R., Haussinger, D., Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 372 (2008), 78–84.
156. [156] Keitel, V., Haussinger, D., TGR5 in the biliary tree. Dig Dis 29 (2011), 45–47.
157. [157] Wagner, M., Halilbasic, E., Marschall, H.U., Zollner, G., Fickert, P., Langner, C., et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 42 (2005), 420–430.
158. [158] Tschuor, C., Kachaylo, E., Limani, P., Raptis, D.A., Linecker, M., Tian, Y., et al. Constitutive androstane receptor (Car)-driven regeneration protects liver from failure following tissue loss. J Hepatol 65 (2016), 66–74.
159. [159] van Dijk, R., Kremer, A.E., Smit, W., van den Elzen, B., van Gulik, T., Gouma, D., et al. Characterization and treatment of persistent hepatocellular secretory failure. Liver Int 35 (2015), 1478–1488.
160. [160] Hayashi, H., Sakai, K., Baba, H., Sakai, T., Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. Hepatology 55 (2012), 1562–1573.
161. [161] Kuroki, H., Hayashi, H., Nakagawa, S., Sakamoto, K., Higashi, T., Nitta, H., et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor beta signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg 102 (2015), 813–825.
162. [162] Stutchfield, B.M., Antoine, D.J., Mackinnon, A.C., Gow, D.J., Bain, C.C., Hawley, C.A., et al. CSF1 Restores Innate Immunity After Liver Injury in Mice and Serum Levels Indicate Outcomes of Patients With Acute Liver Failure. Gastroenterology 149 (2015), 1896–1909, e1814.
163. [163] Forbes, S.J., Gupta, S., Dhawan, A., Cell therapy for liver disease: from liver transplantation to cell factory. J Hepatol 62 (2015), S157–S169.
164. [164] Duncan, A.W., Dorrell, C., Grompe, M., Stem cells and liver regeneration. Gastroenterology 137 (2009), 466–481.
165. [165] Huch, M., Dorrell, C., Boj, S.F., van Es, J.H., Li, V.S., van de Wetering, M., et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 494 (2013), 247–250.
166. [166] Huang, P., Zhang, L., Gao, Y., He, Z., Yao, D., Wu, Z., et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 14 (2014), 370–384.
167. [167] Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T., et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499 (2013), 481–484.
168. [168] Takahashi, K., Yamanaka, S., Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (2006), 663–676.
169. [169] Kimura, F., Shimizu, H., Yoshidome, H., Ohtsuka, M., Kato, A., Yoshitomi, H., et al. Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection. J Surg Res 133 (2006), 102–112.
170. [170] van de Kerkhove, M.P., de Jong, K.P., Rijken, A.M., de Pont, A.C., van Gulik, T.M., MARS treatment in posthepatectomy liver failure. Liver Int 23 (2003), 44–51.
171. [171] van Wenum, M., Chamuleau, R.A., van Gulik, T.M., Siliakus, A., Seppen, J., Hoekstra, R., Bioartificial livers in vitro and in vivo: tailoring biocomponents to the expanding variety of applications. Expert Opin Biol Ther 14 (2014), 1745–1760.
172. [172] Lee, K.C., Baker, L.A., Stanzani, G., Alibhai, H., Chang, Y.M., Jimenez Palacios, C., et al. Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: results of a pivotal pre-clinical study. J Hepatol 63 (2015), 634–642.
173. [173] Larsen, F.S., Schmidt, L.E., Bernsmeier, C., Rasmussen, A., Isoniemi, H., Patel, V.C., et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 64 (2016), 69–78.
174. [174] Rifai, K., Ernst, T., Kretschmer, U., Bahr, M.J., Schneider, A., Hafer, C., et al. Prometheus–a new extracorporeal system for the treatment of liver failure. J Hepatol 39 (2003), 984–990.
175. [175] Otsuka, Y., Duffy, J.P., Saab, S., Farmer, D.G., Ghobrial, R.M., Hiatt, J.R., et al. Postresection hepatic failure: successful treatment with liver transplantation. Liver transpl 13 (2007), 672–679.
176. [176] van den Broek, M.A., van Dam, R.M., Malago, M., Dejong, C.H., van Breukelen, G.J., Olde Damink, S.W., Feasibility of randomized controlled trials in liver surgery using surgery-related mortality or morbidity as endpoint. Br J Surg 96 (2009), 1005–1014.
177. [177] van den Broek, M.A., van Dam, R.M., van Breukelen, G.J., Bemelmans, M.H., Oussoultzoglou, E., Pessaux, P., et al. Development of a composite endpoint for randomized controlled trials in liver surgery. Br J Surg 98 (2011), 1138–1145.
178. [178] Arroyo, V., Moreau, R., Jalan, R., Gines, P., Study E-CCC. Acute-on-chronic liver failure: a new syndrome that will re-classify cirrhosis. J Hepatol 62 (2015), S131–S143.